GeneFerm Biotechnology Valuation
| 1796 Stock | TWD 48.95 0.30 0.61% |
At this time, the firm appears to be overvalued. GeneFerm Biotechnology retains a regular Real Value of NT$40.85 per share. The prevalent price of the firm is NT$48.95. Our model calculates the value of GeneFerm Biotechnology from evaluating the firm fundamentals such as Current Valuation of 2.48 B, return on equity of 0.12, and Return On Asset of 0.0534 as well as inspecting its technical indicators and probability of bankruptcy.
Overvalued
Today
Please note that GeneFerm Biotechnology's price fluctuation is very steady at this time. Calculation of the real value of GeneFerm Biotechnology is based on 3 months time horizon. Increasing GeneFerm Biotechnology's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the GeneFerm stock is determined by what a typical buyer is willing to pay for full or partial control of GeneFerm Biotechnology Co. Since GeneFerm Biotechnology is currently traded on the exchange, buyers and sellers on that exchange determine the market value of GeneFerm Stock. However, GeneFerm Biotechnology's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 48.95 | Real 40.85 | Hype 48.95 | Naive 50.59 |
The intrinsic value of GeneFerm Biotechnology's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence GeneFerm Biotechnology's stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of GeneFerm Biotechnology Co helps investors to forecast how GeneFerm stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of GeneFerm Biotechnology more accurately as focusing exclusively on GeneFerm Biotechnology's fundamentals will not take into account other important factors: GeneFerm Biotechnology Total Value Analysis
GeneFerm Biotechnology Co is presently anticipated to have takeover price of 2.48 B with market capitalization of 3.22 B, debt of 31.25 M, and cash on hands of 619.1 M. Please note that takeover price may be misleading and is a subject to mistakes in financial statements. We encourage investors to thoroughly investigate all of the GeneFerm Biotechnology fundamentals before making investing decisions based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
2.48 B | 3.22 B | 31.25 M | 619.1 M |
GeneFerm Biotechnology Investor Information
About 57.0% of the company shares are owned by insiders or employees . The book value of GeneFerm Biotechnology was presently reported as 19.63. The company last dividend was issued on the 23rd of June 2022. Based on the key measurements obtained from GeneFerm Biotechnology's financial statements, GeneFerm Biotechnology Co is not in a good financial situation at the moment. It has a very high risk of going through financial straits in December.GeneFerm Biotechnology Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. GeneFerm Biotechnology has an asset utilization ratio of 39.66 percent. This indicates that the Company is making NT$0.4 for each dollar of assets. An increasing asset utilization means that GeneFerm Biotechnology Co is more efficient with each dollar of assets it utilizes for everyday operations.GeneFerm Biotechnology Ownership Allocation
GeneFerm Biotechnology Co has a total of 41.46 Million outstanding shares. GeneFerm Biotechnology secures significant amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company's outstanding shares. Since such a large part of the company is owned by insiders, it is advisable to analyze if each of these insiders have been buying or selling the stock in recent months. Please note that no matter how many assets the company holds, if the real value of the firm is less than the current market value, you may not be able to make money on it.GeneFerm Biotechnology Profitability Analysis
The company reported the revenue of 522.33 M. Net Income was 57.41 M with profit before overhead, payroll, taxes, and interest of 192.65 M.About GeneFerm Biotechnology Valuation
Our relative valuation model uses a comparative analysis of GeneFerm Biotechnology. We calculate exposure to GeneFerm Biotechnology's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of GeneFerm Biotechnology's related companies.GeneFerm Biotechnology Co., Ltd. develops, manufactures, markets, and sells fermented products in Taiwan and internationally. The company was founded in 1999 and is based in Taipei City, Taiwan. GENEFERM BIOTECHNOLOGY operates under Drug ManufacturersSpecialty Generic classification in Taiwan and is traded on Taiwan OTC Exchange.
8 Steps to conduct GeneFerm Biotechnology's Valuation Analysis
Company's valuation is the process of determining the worth of any company in monetary terms. It estimates GeneFerm Biotechnology's potential worth based on factors such as financial performance, market conditions, growth prospects, and overall economic environment. The result of company valuation is a single number representing a Company's current market value. This value can be used as a benchmark for various financial transactions such as mergers and acquisitions, initial public offerings (IPOs), or private equity investments. To conduct GeneFerm Biotechnology's valuation analysis, follow these 8 steps:- Gather financial information: Obtain GeneFerm Biotechnology's financial statements, including balance sheets, income statements, and cash flow statements.
- Determine GeneFerm Biotechnology's revenue streams: Identify GeneFerm Biotechnology's primary sources of revenue, including products or services offered, target markets, and pricing strategies.
- Analyze market data: Research GeneFerm Biotechnology's industry and market trends, including the size of the market, growth rate, and competition.
- Establish GeneFerm Biotechnology's growth potential: Evaluate GeneFerm Biotechnology's management, business model, and growth potential.
- Determine GeneFerm Biotechnology's financial performance: Analyze its financial statements to assess its historical performance and future potential.
- Choose a valuation method: Consider the Company's specific circumstances and choose an appropriate valuation method, such as the discounted cash flow (DCF) or comparable analysis method.
- Calculate the value: Apply the chosen valuation method to the financial information and market data to calculate GeneFerm Biotechnology's estimated value.
- Review and adjust: Review the results and make necessary adjustments, considering any relevant factors that may have been missed or overlooked.
Additional Tools for GeneFerm Stock Analysis
When running GeneFerm Biotechnology's price analysis, check to measure GeneFerm Biotechnology's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy GeneFerm Biotechnology is operating at the current time. Most of GeneFerm Biotechnology's value examination focuses on studying past and present price action to predict the probability of GeneFerm Biotechnology's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move GeneFerm Biotechnology's price. Additionally, you may evaluate how the addition of GeneFerm Biotechnology to your portfolios can decrease your overall portfolio volatility.